Compare Aptiv PLC (APTV) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aptiv PLC vs TransMedics Group Inc — how do they compare? Aptiv PLC trades at $48.52 (market cap $10.30B), while TransMedics Group Inc trades at $88.01 (market cap $3.10B). The key difference: Aptiv PLC is far larger — about 3.3× TransMedics Group Inc's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Aptiv PLC nearer its low. Which is the better fit depends on your goals.
| APTV | TMDX | |
|---|---|---|
Market Cap | $10.30B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $76.82 | $150.42 |
52-Week Low | $46.30 | $61.99 |
Enterprise Value | $15.23B | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
APTV trades at $48.38, down 2.87% on the day, reflecting bearish technical signals and recent guidance cuts. The stock shows strong valuation metrics with a P/E of 22.45 and P/S of 0.52, but profitability is weak with a net margin of 1.07%. Recent Q2 2026 earnings beat estimates, but the company lowered its full-year outlook due to China demand issues and launch delays, pressuring investor sentiment.
The outlook is mixed: low valuation and analyst consensus of $70.09 target suggest upside, but near-term execution risks and cash flow pressures create uncertainty. Investment opportunity hinges on margin recovery and China market stabilization, while risks include sustained guidance cuts and competitive pressures in automotive technology.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Aptiv PLC
Aptiv's signal and power solutions segment supplies components and systems that make up a vehicle's electrical system backbone, including wiring assemblies and harnesses, connectors, electrical centers, and hybrid electrical systems. The advanced safety and user experience segment provides body controls, infotainment and connectivity systems, passive and active safety electronics, advanced driver-assist technologies, and displays, as well as the development of software for these systems. Aptiv's largest customer is General Motors at roughly 12% of 2021 revenue, including sales to GM's Shanghai joint venture, followed by Stellantis at 11%, and Volkswagen at 9%. North America and Europe represented approximately 38% and 33% of total 2019 revenue, respectively.
Read more on APTV →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
